Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of GenMark Diagnostics, Inc. (NASDAQ:GNMK) resulting from allegations that GenMark may have issued materially misleading business information to the investing public.

On November 2, 2017, GenMark President and CEO Hany Massarany stated during an earnings conference call that revenue recognition for expected placements of ePlex was slowed by a longer than expected customer evaluation and validation process prior to implementation of ePlex in routine clinical use. On this news, shares of GenMark fell sharply during intraday trading on November 3, 2017.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by GenMark investors. If you purchased shares of GenMark, please visit the firm’s website at http://www.rosenlegal.com/cases-1231.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.